knowledge -WSS

knowledge

author：fashion 2025-09-30 01:12:28 - browse：327

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： STAT Virtual Event: The State of Biosimilars: What to Watch

leisure time

hotspot

WSS

Teachers share how revamped forgiveness program helped with their student loans

Biden’s NIH nominee is languishing in Congress

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Sanders adds drug shortage policies to pandemic preparedness bill

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How one medical school became remarkably diverse

Pandemic and All Hazards Preparedness Act needs lean update

Continuity nursing helped my family in our darkest PICU moments

Judge agrees to delay next hearing in Trump classified documents case

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ACA's risk program benefits Blue Cross Blue Shield insurers

Duchenne breakthrough therapy leaves behind pioneering families

Cosmetics set for new safety regulation. Why the industry is on board

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

explore

Cosmetics set for new safety regulation. Why the industry is on board

How dance can help nurses traumatized by Covid

Medicare has a new plan to address drug shortages

How dance can help nurses traumatized by Covid

Recent heat wave in the Mediterranean caused by climate change: Study

Judge agrees to delay next hearing in Trump classified documents case

leisure time

leisure time

hotspot

knowledge